DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 220 participants.

Also called NCT02110303

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 220 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02110303
Other papers using this trial's data
  • Coronary 18F-Fluoride Uptake and Progression of Coronary Artery Calcification Circulation. Cardiovascular imaging, 2020-12 DOI, PubMed 33297761, PMC7771641 In the PMC Open Access subset under CC BY.
  • Ticagrelor to Reduce Myocardial Injury in Patients With High-Risk Coronary Artery Plaque JACC. Cardiovascular imaging, 2020-07 DOI, PubMed 31422134, PMC7342015 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02110303. Randomized; quadruple masking; primary purpose treatment. Start 2015-03 (registry gives no type); primary completion 2017-05-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury
Acronym
DIAMOND
Intervention (Drug)
Ticagrelor
Intervention (Drug)
Placebo
Lead sponsor
University of Edinburgh (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02110303
Content hash
a2687fe9421d9129fdc360e2b747f68e4e898bc83a34037fd397daf5cf6ac28d